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Objectives The aim of this study was to compare the 3-year efficacy and safety of biodegradable polymer with permanent
polymer stents and of everolimus-eluting stents (EES) with sirolimus-eluting stents (SES).
Background Biodegradable polymer drug-eluting stents (DES) offer potential for enhanced late outcomes in comparison with
permanent polymer stents. In addition, there is increasing interest in the comparison of EES (Xience, Abbott
Vascular, Abbott Park, Illinois) versus SES (Cypher, Cordis Corporation, Miami Lakes, Florida).
Methods The ISAR-TEST 4 (Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents-4) was
a randomized clinical trial with broad inclusion criteria, enrolling 2,603 patients at 2 clinics in Munich, Germany.
Patients were randomized to either biodegradable polymer (n  1,299) or permanent polymer stents (n 
1,304); patients treated with permanent polymer stents were randomly allocated to EES (n  652) or SES (n 
652). The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction, or
target lesion revascularization.
Results Clinical events continued to accrue at a low rate out to 3 years in all groups. Overall, there was no significant
difference between biodegradable polymer and permanent polymer DES with regard to the primary endpoint
(20.1% vs. 20.9%, hazard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.80 to 1.13; p  0.59). Rates of defi-
nite/probable stent thrombosis were also similar in both groups (1.2% vs. 1.7%, respectively; HR: 0.71, 95% CI:
0.37 to 1.39; p  0.32). In patients treated with permanent polymer stents, EES were comparable to SES with
regard to the primary endpoint (19.6% vs. 22.2%, respectively; HR: 0.87, 95% CI: 0.68 to 1.11; p  0.26) as
well as definite/probable stent thrombosis (1.4% vs. 1.9%, HR: 0.75, 95% CI: 0.32 to 1.78; p  0.51).
Conclusions Biodegradable polymer and permanent polymer DES are associated with similar clinical outcomes at 3 years. In addi-
tion, EES are comparable to SES in terms of overall clinical efficacy and safety. (Intracoronary Stenting and Angio-
graphic Results: Test Efficacy of 3 Limus-Eluting STents [ISAR-TEST 4]: Prospective, Randomized Trial of 3-limus
Agent-eluting Stents With Different Polymer Coatings; NCT00598676) (J Am Coll Cardiol 2011;58:1325–31)
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3-Year Results of the ISAR-TEST 4 Trial September 20, 2011:1325–31Although first-generation drug-
eluting stents (DES) are highly
effective at preventing coronary
restenosis, there is a collateral
cost to be borne in terms of
delayed healing of the stented
arterial segment (1–3). Therefore,
the motivation behind the devel-
opment of newer devices has
been the attainment of optimal
antirestenotic efficacy at a minimum
of arterial wall toxicity (4).
Biodegradable polymer DES
offer controlled elution of active-
rug from the stent backbone by means of a biocompatible
olymer coating, which after completion of its useful func-
ion, slowly degrades to inert organic monomers, thereby
issipating the risk associated with the long-term presence
f durable polymer in the coronary vessel wall. To date, 2
arge-scale studies have demonstrated noninferiority of bio-
egradable polymer DES against standard-bearer perma-
ent polymer DES at 1 year (5,6), but longer-term data
ith this therapy remain scant.
In terms of permanent polymer DES, the everolimus-
luting stent (EES) (Xience, Abbott Vascular, Abbott Park,
llinois) represents a potential step forward in stent technology.
t has proven superior to the first-generation paclitaxel-eluting
tent (Taxus, Boston Scientific, Natick, Massachusetts) in a
umber of randomized controlled studies (7,8), although
enchmark evaluation against the standard-bearer first-
eneration sirolimus-eluting stent (SES) (Cypher, Cordis Cor-
oration, Miami Lakes, Florida) in broadly inclusive lesion and
atient subtypes remains a scientific gap.
We sought to address these outstanding issues by comparing
he clinical efficacy and safety of biodegradable polymer stents
ith permanent polymer stents and of EES with SES at 3-year
ollow-up in the setting of the ISAR-TEST 4 (Intracoronary
tenting and Angiographic Results: Test Efficacy of 3 Limus-
luting Stents-4) trial.
ethods
he ISAR-TEST 4 trial was an investigator-initiated,
ndustry-independent, real-world randomized trial with broad
nclusion criteria. The primary study comparison was between
utcomes of patients treated with biodegradable polymer
ersus permanent polymer DES. The secondary study com-
arison was between outcomes of patients treated with EES
ersus SES. Details of the study population, methods, end-
oints, and primary analysis have been previously reported (6).
Patients were assigned to receive biodegradable polymer
SES [stent backbone produced by Translumina, Hechingen,
ermany]) or permanent polymer DES (either EES, Xience
Abbott Vascular], or SES, Cypher [Cordis Corporation]) in a
:1:1 allocation. Full description of the biodegradable polymer
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MI  myocardial infarction
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationtent platform has been reported previously (6).The primary outcome of the ISAR-TEST 4 study was a
evice-oriented composite of cardiac death, myocardial
nfarction (MI) related to the target vessel, or revasculariza-
ion related to the target lesion (TLR).
ollow-up and analysis. Patients were evaluated at 1, 12,
4, and 36 months by telephone call or office visit. Repeat
oronary angiography was scheduled for 6 to 8 months, and in
hose patients undergoing angiographic surveillance at this
ime point and not requiring TLR, a second angiographic
ollow-up was planned for 2 years. All events were adjudicated
nd classified by an event adjudication committee blinded to
he treatment groups. Details relating to statistical analyses are
resented in the Online Appendix.
esults
total of 2,603 patients were randomized to receive biode-
radable polymer (n  1,299) or permanent polymer (n 
,304) DES (Fig. 1). Baseline patient and lesion characteristics
ccording to randomization to biodegradable polymer or per-
anent polymer DES were well balanced in both groups, as
reviously reported, and shown in Online Table 1.
Patients allocated to treatment with permanent polymer
ES were randomized to either EES (Xience, n  652) or
ES (Cypher, n  652) (Fig. 1). Baseline patient and lesion
haracteristics according to randomization to EES or SES are
hown in Table 1.
iodegradable polymer versus permanent polymer DES:
-year clinical follow-up. The results of follow-up are sum-
arized in Table 2. At 3 years, the incidence of the primary
omposite endpoint of cardiac death/MI related to target
essel/TLR was not significantly different between biodegrad-
Figure 1 The ISAR-TEST 4 Study Flow Chart
Participant flow through the study.
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September 20, 2011:1325–31 3-Year Results of the ISAR-TEST 4 Trialable polymer and permanent polymer DES (20.1% vs.
20.9% respectively, hazard ratio [HR]: 0.95, 95% confi-
dence interval [CI]: 0.80 to 1.13; p  0.59) (Fig. 2A). The
comparability between the 2 study devices with regard to the
primary endpoint was observed across all pre-specified
subgroups (Online Fig. 1).
In terms of antirestenotic efficacy, TLR at 3 years was also
similar in both groups (Fig. 2B). With regard to safety
outcomes, the incidence of adverse events between 1 and 3
years was low across the treatment groups. The composite of
cardiac death/MI related to the target vessel was similar
(Fig. 2C), and the rate of definite/probable stent thrombosis
was low in both groups: 1.2% with biodegradable polymer
DES versus 1.7% with permanent polymer DES (HR: 0.71,
95% CI: 0.37 to 1.39; p  0.32) (Fig. 2D). Full results of
EES Versus SES: Characteristics of Patients anTable 1 EES Versus SES: Characteristics of
Patients n
Age, yrs 66
Male 50
Diabetes mellitus 18
Insulin-dependent 6
Arterial hypertension 44
Hyperlipidemia 42
Current smoker 10
Prior myocardial infarction 19
Prior coronary artery bypass grafting 6
Clinical presentation
Acute myocardial infarction 7
Unstable angina 19
Stable angina 38
Ejection fraction, %* 53
Multilesion intervention 17
Multivessel disease 55
Lesions n
Target vessel location
Left anterior descending artery 37
Left circumflex artery 22
Right coronary artery 25
Chronic total occlusion 3
Bifurcation 18
Ostial 15
Complex morphology (B2/C) 60
Lesion length, mm 15
Vessel size, mm 2.8
Minimum lumen diameter, mm
Before procedure 0.9
After procedure 2.5
Percent stenosis, %
Before procedure 64
After procedure, in-stent 11
After procedure, in-segment 23
Values are mean  SD or n (%). *Data available for 1,149 patients (8
EES  everolimus-eluting stent(s); SES  sirolimus-eluting stent(s).stent thrombosis adjudication are presented in Table 2. tEverolimus-eluting versus SES: 3-year clinical follow-up.
The results of follow-up are summarized in Table 3. The
incidence of the primary composite endpoint of cardiac
death/MI related to target vessel/TLR was not signifi-
cantly different between EES and SES (19.6% vs. 22.3%,
respectively; HR: 0.87, 95% CI: 0.68 to 1.11; p  0.26)
Fig. 3A). The comparability between the 2 study devices
ith regard to the primary endpoint was observed across
ll pre-specified subgroups (Online Fig. 2).
In terms of antirestenotic efficacy, there was a numer-
cally lower rate of TLR at 3 years with EES versus SES,
lthough this was not statistically significant (Fig. 3B).
ith regard to safety outcomes, the composite of cardiac
eath/MI related to the target vessel was similar in both
roups (Fig. 3C). The rate of definite/probable stent
ions at Baselineents and Lesions at Baseline
SES p Value
2 n  652
0.3 66.8 11.1 0.93
.8) 495 (75.9) 0.43
.2) 193 (29.6) 0.58
) 62 (9.5) 0.85
.8) 439 (67.3) 0.86
.9) 423 (64.6) 0.99
.5) 114 (17.5) 0.33
.3) 182 (27.9) 0.58
) 60 (9.2) 0.40
0.49
) 70 (10.7)
.6) 180 (27.6)
.7) 402 (61.7)
1.7 53.8 12.1 0.64
.7) 166 (25.5) 0.61
.4) 569 (87.3) 0.33
0 n  839
0.59
.8) 376 (44.8)
.2) 230 (27.4)
.0) 233 (27.8)
) 50 (6.0) 0.11
.8) 198 (23.6) 0.37
.6) 146 (17.4) 0.53
.1) 614 (73.2) 0.33
.9 14.8 8.2 0.37
.45 2.80 0.48 0.82
.49 0.97 0.51 0.48
.45 2.59 0.44 0.94
6.0 65.4 16.1 0.51
.3 10.8 6.2 0.001
1.4 23.3 10.8 0.64d LesPati
EES
 65
.7 1
7 (77
4 (28
0 (9.2
2 (67
3 (64
1 (15
1 (29
9 (10.6
0 (10.7
9 (30
3 (58
.4 1
4 (26
7 (85
 85
2 (43
3 (26
5 (30
6 (4.2
5 (21
8 (18
4 (71
.2 8
0 0
9 0
9 0
.8 1
.8 6
.6 1hrombosis at 3 years was 1.4% with EES versus 1.9%
eath, t
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3-Year Results of the ISAR-TEST 4 Trial September 20, 2011:1325–31with SES (relative risk: 0.75, 95% CI: 0.32 to 1.78; p 
0.51) (Fig. 3D). Full results of stent thrombosis adjudi-
cation are presented in Table 3.
Figure 2 Comparison of Outcomes in Patients Treated With Bio
Kaplan-Meier curves for (A) primary endpoint (composite of cardiac death, target vess
(B) target lesion revascularization, (C) all-cause death, and (D) definite/probable sten
Biodegradable Polymer Versus Permanent Polymer Drug-Eluting SteTable 2 Biodegradable Polymer Versus Per anent Polymer Dru
Biodegradable Polymer Stents
(n  1,299)
All-cause death 117 (9.3)
Cardiac death 58 (4.7)
Target vessel myocardial infarction 59 (4.6)
Cardiac death or target vessel
myocardial infarction
107 (8.5)
TLR 168 (13.9)
Primary endpoint* 252 (20.1)
Stent thrombosis
Definite 9 (0.7)
Probable 6 (0.5)
Possible 12 (1.0)
Definite or probable 15 (1.2)
Values are n (percentage as Kaplan-Meier estimate). *Primary endpoint  composite of cardiac d
CI  confidence interval; HR  hazard ratio.Additional analyses. Results relating to patient-oriented
outcomes did not differ across the groups and are pre-
sented in the Online Appendix. Landmark analyses at
adable Polymer Versus Permanent Polymer DES
cardial infarction, or target lesion revascularization),
bosis. CI  confidence interval; DES  drug-eluting stent; HR  hazard ratio.
Clinical Outcomes Out to 3 Yearsting Stents: Clinical Outcomes Out to 3 Years
Permanent Polymer Stents
(n  1,304) HR (95% CI) p Value
123 (9.8) 0.95 (0.74–1.23) 0.71
65 (5.2) 0.89 (0.63–1.27) 0.53
56 (4.4) 1.06 (0.73–1.52) 0.77
112 (8.9) 0.96 (0.73–1.25) 0.75
172 (14.2) 0.97 (0.78–1.20) 0.79
263 (20.9) 0.95 (0.80–1.13) 0.59
13 (1.0) 0.69 (0.30–1.62) 0.39
8 (0.6) 0.75 (0.26–2.16) 0.59
15 (1.2) 0.80 (0.38–1.71) 0.57
21 (1.7) 0.71 (0.37–1.39) 0.32
arget vessel myocardial infarction, or target lesion revascularization (TLR).degr
el myo
t thromnts:g-Elu
eath, t
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September 20, 2011:1325–31 3-Year Results of the ISAR-TEST 4 Trial1 year are shown in Online Table 2. Quantitative coro-
nary angiographic analysis results at 6 to 8 months and at
2 years for biodegradable polymer versus permanent
Figure 3 Comparison of Outcomes in Patients Treated With Ev
Kaplan-Meier curves for (A) primary endpoint (composite of cardiac death, target v
(B) target lesion revascularization, (C) all-cause death, and (D) definite/probable
EES Versus SES: Clinical Outcomes Out to 3 YearsTable 3 EES Versus SES: Clinical Outcomes Out to 3 Years
EES (n  652)
All-cause death 58 (9.3)
Cardiac death 31 (5.0)
Target vessel myocardial
infarction
26 (4.1)
Cardiac death or target vessel
myocardial infarction
55 (8.7)
TLR 77 (12.8)
Primary endpoint* 123 (19.6)
Stent thrombosis
Definite 4 (0.6)
Probable 5 (0.8)
Possible 5 (0.8)
Definite or probable 9 (1.4)
Values are n (percentage as Kaplan-Meier estimate). *Primary endpoint  composite of cardiac d
CI  confidence interval; HR  hazard ratio.polymer DES and EES versus SES are shown in the
Online Appendix and detailed in Online Tables 3 and 4,
respectively.
us-Eluting Versus Sirolimus-Eluting Stents
myocardial infarction, or target lesion revascularization),
hrombosis. Abbreviations as in Figure 2.
ES (n  652) HR (95% CI) p Value
65 (10.3) 0.90 (0.63–1.29) 0.57
34 (5.4) 0.92 (0.56–1.49) 0.73
30 (4.7) 0.87 (0.51–1.47) 0.60
57 (9.0) 0.97 (0.67–1.41) 0.88
95 (15.5) 0.80 (0.59–1.08) 0.15
140 (22.3) 0.87 (0.68–1.11) 0.26
9 (1.4) 0.44 (0.14–1.44) 0.16
3 (0.5) 1.67 (0.40–6.99) 0.48
10 (1.7) 0.50 (0.17–1.47) 0.20
12 (1.9) 0.75 (0.32–1.78) 0.51
arget vessel myocardial infarction, or TLR.erolim
essel
stent tS
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The current paper reports the 3-year outcomes from a
large-scale randomized trial with broad inclusion criteria,
comparing outcomes of patients treated with biodegradable
polymer versus permanent polymer DES and EES versus
SES. The salient findings are: 1) biodegradable polymer and
permanent polymer DES are associated with similar clinical
outcomes at 3 years; 2) in patients treated with permanent
polymer DES, EES stents are associated with similar
clinical outcomes in comparison with SES; and 3) clinical
events continued to accrue at a low rate out to 3 years,
although rates of stent thrombosis were low across all
treatment groups.
Biodegradable polymer versus permanent polymer DES.
The present trial is the largest completed randomized trial
involving patients treated with biodegradable polymer DES.
The principal finding was that, in terms of clinical events,
there was no significant difference in outcomes between
patients treated with biodegradable polymer or permanent
polymer DES. Notably, although a numerically lower rate
of definite/probable stent thrombosis was observed with
biodegradable polymer DES, this difference was not statis-
tically significant, and the 95% CIs surrounding the risk
reduction are broad and overlapping, reflecting the overall
low incidence of events. This is an ongoing issue in trials of
emerging DES technology, making the design of trials pow-
ered to detect safety benefit with comparator stents largely
infeasible. In time, however, aggregate long-term data from
completed or ongoing biodegradable polymer trials might
conceivably shed some further light on this question.
EES versus SES. There is increasing interest in the com-
parison between the EES (Xience) and SES (Cypher).
Although the EES has proven superior to the first-
generation paclitaxel-eluting (Taxus) stent (7,8), it is well-
recognized that this stent is a weak comparator (1). Indeed,
benchmark evaluation against the SES Cypher in the setting
of a randomized trial is imperative, before we can fully
define the role of EES in contemporary practice.
The main finding of the ISAR-TEST 4 trial in this
respect was that in a broadly inclusive patient cohort EES
are associated with similar clinical outcomes in comparison
with SES out to 3 years. These observations are in line with
a recently published 2-year comparative analysis of both
stents in large vessels (9) and also with the 9-month results
from a second randomized trial (10). Furthermore, although
there was no significant difference between the 2 stent
platforms in terms of safety, the numerically lower rates of
stent thrombosis observed with the EES seems to be a
consistent feature of clinical trials with this stent. Moreover,
the remarkably low incidence of definite stent thrombosis of
0.6% observed with EES at 3 years in the present study is in
line with rates seen in other studies (7,8). Finally, in terms of
antirestenotic performance, although there was no statistically
significant difference in clinical efficacy, a trend was observed infavor of the everolimus-eluting stent in terms of both angiographic
and clinical outcomes.
Strengths and limitations of ISAR-TEST 4. In terms of
strengths, the present study is notable for its broad inclusion
criteria. Furthermore, patient and lesion complexity was
high, reflective of routine clinical practice at the enrolling
institutions, where the overwhelming majority (90%) of
patients consent to participation in randomized clinical
trials. Consequently, results are likely to be generalizable.
Furthermore, the availability of outcome data out to 3 years
permits capture of relatively late-occurring adverse safety
and efficacy events.
In terms of limitations, the primary design of the ISAR-
TEST 4 trial was a noninferiority comparison of biodegrad-
able and permanent polymer DES at 12 months. Additional
comparisons at 3 years should be regarded as post hoc.
Furthermore, although comparison between EES and SES
was pre-specified, the trial was not specifically powered for
this comparison. In addition, the influence of angiographic
follow-up on the individual components of the primary
endpoint should be considered. Finally, although both
treatment groups received the same recommendation for
duration of treatment after stenting, complete data relating
to actual duration of dual antiplatelet therapy was not
available.
Conclusions
In a real-world trial with broad inclusion criteria enrolling
patients with stable coronary disease or acute coronary
syndromes, biodegradable polymer and permanent polymer
DES are associated with similar clinical outcomes out to 3
years. In addition, in patients treated with permanent
polymer DES, both EES and SES are associated with
comparable outcomes over the same time period.
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